Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation
Pan-Yu Chen, Benjamin J. Huang, Max Harris, Christopher Boone, Weijie Wang, Heidi Carias, Brian Mesiona, Daniela Mavrici, Amanda C. Kohler, Gideon Bollag, Chao Zhang, Ying Zhang, Kevin Shannon
Pan-Yu Chen, Benjamin J. Huang, Max Harris, Christopher Boone, Weijie Wang, Heidi Carias, Brian Mesiona, Daniela Mavrici, Amanda C. Kohler, Gideon Bollag, Chao Zhang, Ying Zhang, Kevin Shannon
View: Text | PDF
Research Article Oncology

Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation

  • Text
  • PDF
Abstract

A T50I substitution in the K-Ras interswitch domain causes Noonan syndrome and emerged as a third-site mutation that restored the in vivo transforming activity and constitutive MAPK pathway activation by an attenuated KrasG12D,E37G oncogene in a mouse leukemia model. Biochemical and crystallographic data suggested that K-RasT50I increases MAPK signal output through a non-GTPase mechanism, potentially by promoting asymmetric Ras:Ras interactions between T50 and E162. We generated a “switchable” system in which K-Ras mutant proteins expressed at physiologic levels supplant the fms like tyrosine kinase 3 (FLT3) dependency of MOLM-13 leukemia cells lacking endogenous KRAS and used this system to interrogate single or compound G12D, T50I, D154Q, and E162L mutations. These studies support a key role for the asymmetric lateral assembly of K-Ras in a plasma membrane–distal orientation that promotes the formation of active Ras:Raf complexes in a membrane-proximal conformation. Disease-causing mutations such as T50I are a valuable starting point for illuminating normal Ras function, elucidating mechanisms of disease, and identifying potential therapeutic opportunities for Rasopathy disorders and cancer.

Authors

Pan-Yu Chen, Benjamin J. Huang, Max Harris, Christopher Boone, Weijie Wang, Heidi Carias, Brian Mesiona, Daniela Mavrici, Amanda C. Kohler, Gideon Bollag, Chao Zhang, Ying Zhang, Kevin Shannon

×

Figure 1

Regulatable K-Ras expression in FLT3-dependent MOLM-13 KRASKO cells.

Options: View larger image (or click on image) Download as PowerPoint
Regulatable K-Ras expression in FLT3-dependent MOLM-13 KRASKO cells.
(A)...
(A) KRASKO clones 1 and 24 were generated from MOLM-13 cells by CRISPR/Cas9-mediated editing. Western blotting verified loss of K-Ras protein expression (top), and Sanger sequencing confirmed biallelic frameshift insertion–deletion mutations in both clones (bottom). (B) Flow cytometry analysis of KRASKO clone 24 cells expressing individual dox-inducible EGFP–K-Ras fusion proteins. Exposure to 2 μg/mL dox consistently induced EGFP–K-Ras expression in greater than 80% of events analyzed in clone 24 cells expressing EGFP–K-RasWT, EGFP–K-RasG12D, EGFP–K-RasT50I, or EGFP–K-RasG12D,T50I. (C) Western blotting of lysates prepared from the clone 24 cells shown in B demonstrates comparable levels of EGFP–K-Ras in KRASKO cells (~50 kDa due to addition of the EGFP cassette) and endogenous K-Ras (21 kDa) in parental MOLM-13 cells.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts